Plain-English translation of NCT06784791 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called amivantamab, which is an antibody designed to fight lung cancer cells that have specific genetic mutations. The study will give patients this medication (alone in the first group, or combined with chemotherapy in the second group) for four weeks before their scheduled surgery. The goal is to see if this treatment can safely shrink tumors and make surgery more effective.
For patients with early-stage lung cancer that has specific genetic mutations, doctors want to find better ways to treat the cancer before surgery. This medication may help shrink tumors before surgery, potentially making the operation more successful and improving long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the new medication as outpatient infusions over four weeks (with treatment days spread across those weeks). Some patients will receive the medication alone, while others will also receive chemotherapy on the first day. After the four weeks of treatment, you will have surgery to remove the cancer, followed by any other standard care your doctors recommend. Throughout the study, you'll have regular blood tests and scans to monitor how you're responding.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Belgium
Germany
Netherlands